Effect of nebulized Salbutamol versus Epinephrine in treatment of transient tachypnea of neonates
Phase 3
Recruiting
- Conditions
- Transient Tachypnea of Neonates.Transient tachypnea of newbornP22.1
- Registration Number
- IRCT20221028056324N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Transient tachypnea of neonates
Neonatal intensive care unit
Exclusion Criteria
First minute apgar below 4
Respiratory distress syndrome caused by surfactant deficiency
Congenital anomalies
Syndromes of chromosomal disorders
Congenital heart diseases
Premature neonatal sepsis
Meconium aspiration
Infants with metabolic disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Respiratory rate. Timepoint: Half an hour, one hour and four hours after nebulizer administration. Method of measurement: Physical examination.;Heart rate. Timepoint: Half an hour, one hour and four hours after nebulizer administration. Method of measurement: Noninvasive pulsoxymetry.;Oxygen saturation. Timepoint: Half an hour, one hour and four hours after nebulizer administration. Method of measurement: Noninvasive pulsoxymetry.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nebulized Salbutamol and Epinephrine in treating transient tachypnea of neonates (P22.1)?
How does nebulized Salbutamol compare with standard-of-care treatments for transient tachypnea of newborns in clinical efficacy?
Are there specific biomarkers that predict neonatal response to nebulized beta-agonists or adrenergic agents in transient tachypnea (P22.1)?
What are the known adverse events associated with nebulized Epinephrine in neonatal intensive care units and how are they managed?
What combination therapies or alternative drugs are being explored alongside nebulized Salbutamol and Epinephrine for neonatal respiratory conditions like P22.1?